Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Olema PharmaceuticalsOLMA +4.26%28 12-1 Month Momentum % is 133.64% as of Aug. 05, 2026. GuruFocus rates OLMA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,361 Biotechnology companies, Olema Pharmaceuticals ranks better than 89.35% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-05), Olema Pharmaceuticals's 12-1 Month Momentum % is 133.64%.
The industry rank for Olema Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
OLMA's 12-1 Month Momentum % is ranked better than 89.35% of 1361
companies
in the Biotechnology industry
Industry Median: -14.9
vs OLMA: 133.64
Olema Pharmaceuticals (NAS:OLMA) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Olema Pharmaceuticals 12-1 Month Momentum % Related Terms
OLMA vs EYPT, LXRX, ANRO: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Olema Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olema Pharmaceuticals 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Olema Pharmaceuticals's 12-1 Month Momentum % falls into.
Olema Pharmaceuticals (NAS:OLMA) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 133.64% mean?
Olema Pharmaceuticals (OLMA) has a 12-1 Month Momentum % of 133.64% as of Aug. 05, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Olema Pharmaceuticals and its competitors. According to the industry distribution chart, Olema Pharmaceuticals ranks #145 out of 1361 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Olema Pharmaceuticals' 12-1 Month Momentum % too high?
Olema Pharmaceuticals' current 12-1 Month Momentum % is 133.64%. Based on the distribution chart, Olema Pharmaceuticals ranks #145 out of 1361 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Olema Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Olema Pharmaceuticals' 12-1 Month Momentum % compare to EYPT and LXRX?
According to the Biotechnology industry distribution chart, Olema Pharmaceuticals ranks #145 out of 1361 companies for 12-1 Month Momentum %. This places Olema Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Olema Pharmaceuticals and its competitors. Olema Pharmaceuticals's current 12-1 Month Momentum % is 133.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olema Pharmaceuticals stock overvalued right now?
Olema Pharmaceuticals (OLMA) has a current 12-1 Month Momentum % of 133.64%. The current 12-1 Month Momentum % is 133.64%. Olema Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Olema Pharmaceuticals (OLMA), the current 12-1 Month Momentum % is 133.64% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
28GF Score
Get the complete analysis for OLMA
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OLMA has been successfully added to your 
